ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SIBN
IRMD (55) IART (19) BBNX (36) SGP (43) ⌘ Pro Terminal →

SI-BONE Inc. (SIBN) — RQD Stock Rating Cockpit

$20.22 -4.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.01

SI-BONE Inc. (SIBN) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $951.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SIBN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SIBN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, SI-BONE Inc. (NASDAQ: SIBN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $20.22 (-4.76% 1D, market cap $951.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SIBN ranks #244 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SIBN compare to IRMD and IART in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), SIBN carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 79.6%, and ROIC of -10.3%. By comparison, IRMD (iRadimed Corporation) holds a D+ grade (55/100 RQD, P/E 48.8x, ROIC 37.7%, cap $980.5M) and IART (Integra LifeSciences Holdings Corporation) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $992.0M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SIBN?
▼

Per SIBN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001459839), SI-BONE Inc. generated $200.9M in revenue (+20.2% YoY), -$18.9M in net income, and -$9.1M in free cash flow against $238.6M in total assets and $35.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $20.01 (-1.05%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510052
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-
Cash (9)Whales (16)SEC (14)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-2.7% Base Target
$24 Bull$20 Base$15 Bear
📬 FREE SIBN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SIBN)Realized 20D OHLCV Swing Band: ±8.1%
Deterministic 5-Pillar Attribution (52/100 Composite)
🔍 WHY SIBN SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (31% of score)

20D Institutional Volume Accumulation (±8.1% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (27% of score)

Altman Z-Score 8.73 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$19.68+4.4% Next Q
Q2 (-2Q)
47
Grade D$20.54+4.4% Next Q
Q3 (-1Q)
49
Grade D$21.44-5.7% Next Q
Current
52
Grade D+$20.22-1.1% Hist 90D α
Trajectory: D (44) → D+ (52)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SIBN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SIBN currently carries a cautious 52/100 (D+) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.50) and Max Pain ($21.23) forces dealer call-delta covering toward $24.10.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SIBN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SIBN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 52%NO 48%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
55.430 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
8.73>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
6 / 99-Pt Accounting
52-WEEK LASER RANGE76% OF RANGE
L: $11$20.22H: $23
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on SIBN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (45)

-10.3% ROIC with 79.6% gross margin and -0.90% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 8.73 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (48)

19/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like SIBN
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SIBN)

  • ✓Walkthrough of SIBN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SIBN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +51.46%▲ ASCENDING CHANNEL
2026-11-03O $22.41H $22.41L $20.22C $20.22VOL 1.25M
RES: $23.13SUP: $18.69SMA50: $19.50SMA200: $16.44
$23.75$20.43$17.10$13.77$10.45RES $23.13SUP $18.69$20.222026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SIBN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SIBN Butterfly Map → + Track SIBN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +20.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SIBN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SIBN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SIBN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SIBN)

Health Care Rank #244 of 1015 ⚔️ IRMD vs SIBN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SIBN vs. IRMD, IART, BBNX, SGP)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SI-BONE Inc. (SIBN) ranks #244 by composite RQD confidence (52/100, grade D+) and #362 by equity capitalization ($951.5M). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with SIBN at 52/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SIBN ACTIVE
SI-BONE Inc.
D+ 52/100 — 79.6% -10.3% -4.76% $951.5M Benchmark Subject
IRMD
iRadimed Corporation
D+ 55/100 48.8x 76.7% 37.7% +3.57% $980.5M /irmd-vs-sibn →
IART
Integra LifeSciences Holdings Corporation
E 19/100 — 50.9% -35.0% +6.75% $992.0M /iart-vs-sibn →
BBNX
Beta Bionics Inc.
D- 36/100 — 55.4% -22.1% -5.07% $910.6M /bbnx-vs-sibn →
SGP
SpyGlass Pharma Inc.
D- 43/100 — — -35.0% +4.34% $1.08B /sgp-vs-sibn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001459839 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SI-BONE Inc. (SIBN) reported GAAP revenue of $200.9M (+20.2% vs. FY2024 revenue of $167.2M , and +44.7% cumulative change since FY2023) , GAAP net income of -$18.9M, operating cash flow of -$675.0K, and free cash flow of -$9.1M (+60.3% YoY). On the balance sheet, SIBN closed FY2025 with $238.6M in total assets against $35.6M in total debt (Altman Z-Score: 8.73, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $200.9M -$18.9M -$675.0K -$9.1M $238.6M $35.6M
FY2024 (FY) 2024-12-31 $167.2M -$30.9M -$12.4M -$22.9M $230.4M $35.5M
FY2023 (FY) 2023-12-31 $138.9M -$43.3M -$18.7M -$18.7M — —

3. SIBN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SIBN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, SI-BONE Inc. (NASDAQ: SIBN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $20.22 (-4.76% 1D, market cap $951.5M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SIBN ranks #244 in composite RQD confidence.

How does SIBN compare to IRMD and IART in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SIBN carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 79.6%, and ROIC of -10.3%. By comparison, IRMD (iRadimed Corporation) holds a D+ grade (55/100 RQD, P/E 48.8x, ROIC 37.7%, cap $980.5M) and IART (Integra LifeSciences Holdings Corporation) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $992.0M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SIBN?

Per SIBN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001459839), SI-BONE Inc. generated $200.9M in revenue (+20.2% YoY), -$18.9M in net income, and -$9.1M in free cash flow against $238.6M in total assets and $35.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SIBN trading relative to its 50-day, 200-day, and 52-week technical levels?

SIBN last traded at $20.22 (-4.76% on volume of 1,371,822 shares), positioning the stock +3.69% above its 50-day simple moving average ($19.50) and +22.99% above its 200-day simple moving average ($16.44). Across its 52-week range of $11.48 to $22.95, SIBN sits at the 76.2% percentile with a 14-day RSI of 55.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.1% ($18.58 to $21.86).

Direct Sub-Reports: SIBN RQD Cockpit SIBN 12M Forecast SIBN Earnings & Move SIBN Dividends & DRIP SIBN Insiders & 13F SIBN Whale Options SIBN Profit Sankey SIBN News & Why
ROARABLE RATING BRIEF • RQD 52/100 (D+) ✓ SEC XBRL & RQD VERIFIED

SIBN — SI-BONE Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SI-BONE Inc. (SIBN) earns a live Roarable RQD composite score of 52/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $20.22 (-4.76% 1D, market capitalization $951.5M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -10.3%, gross margin of 79.6%, operating margin of -11.1%, and free cash flow yield of -0.90%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 8.73, Piotroski F-Score of 6/9, and Debt/Equity of 0.20x.

2. Business Model, Unit Margins & SEC Financial Trajectory

SI-BONE Inc. Is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry..0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SI-BONE Inc. (SIBN) reported $200.9M in annual revenue (up from $167.2M in FY2024, +20.2% YoY) and -$18.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($138.9M revenue, -$43.3M net income) through FY2025, SIBN scaled operating cash flow to -$675.0K and free cash flow to -$9.1M, backed by $238.6M in total assets against $35.6M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 52/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -0.90% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $11.48 – $22.95 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -11.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), SIBN carries a macro regime beta of 1.00 and gross margin of 79.6%.

  • Key Question #1: Can SIBN sustain or expand its -11.1% operating margin and -10.3% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $200.9M and free cash flow of -$9.1M, how will capital allocation balance growth reinvestment against $35.6M in total debt?
  • Key Question #3: How sensitive is SIBN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SIBN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SI-BONE Inc. (SIBN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SIBN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SIBN Bull vs. Bear Conversation Board — What's Your Call at $20.22?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SIBN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SIBN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $27.81 (+31.0%)
📌 Pinned Debate

Revenue grew from $138.9M in FY 2023 to $200.9M in FY 2025 with a Debt/Equity of 0.2 and an Altman Z of 8.73, while the whale 13F flow

Don't sleep on SIBN's setup in Health Care. Revenue grew from $138.9M in FY 2023 to $200.9M in FY 2025 with a Debt/Equity of 0.2 and an Altman Z of 8.73, while the whale 13F flow pillar scores 17 of 20.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (52/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

Both sides have a point here — SIBN's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $18.26 (-14.0%)
Spot @ $21.23

ROIC of -10.3%, FCF yield of -0.9%, and an insider conviction pillar score of 3 of 20 indicate the cash engine and insider signals do n

Fading this rally in SIBN at $21.23. ROIC of -10.3%, FCF yield of -0.9%, and an insider conviction pillar score of 3 of 20 indicate the cash engine and insider signals do not yet support the stock's valuation.. With a beta of 1.0 and the stock sitting at $21.23 (52-wk range $11.48–$22.95), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%